Amended Current Report Filing (8-k/a)
November 16 2020 - 06:17AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): November 9,
2020
America Great Health
(Exact name of registrant as specified in charter)
WYOMING
(State or other jurisdiction of incorporation)
0-27873
|
|
98-0178621
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
1609 W Valley Blvd., #338,
Alhambra, CA
|
|
91803
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant's telephone number, including area
code: (626) 576-1299
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
☐ Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
☐ Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 5.02. DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS;
ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS;
COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS
On October 7th, 2018, the Company announced that Mr. Jiaxin Xue was
appointed to the Company's Board of Directors and Executive Vice
Chairman, also the Chief Executor of China Branch, and on January
12th, 2018, the Company announced that Mr. Rex Chang was appointed
to the Company’s Board of Director and Executive Vice
Chairman.
Mr. Jiaxin Xue is graduate from Henan Medical University, he also
obtain Doctor degree in Natural Medicine from American Naturopathic
University, Master's degree in Social Medicine and Health
Management from Peking Union Medical College, Mr. Xue obtained PhD
degree in Social Economics, School of Philosophy and Sociology from
Beijing Normal University. He is an experienced specialist involves
comprehensive fields such as medical treatment, medicine, health,
rehabilitation, and elderly care. It mainly focuses on the
interpretation and analysis of national pharmaceutical policies and
regulations and medical environment safety, strategic management of
pharmaceutical projects and strategic planning and operation,
project branding and business diagnosis analysis, and optimization
of pharmaceutical market management Operation strategy diagnosis,
project performance evaluation and economic market risk analysis,
brand marketing system construction and chain operation management,
pharmaceutical investment and financing management and operational
risk control, etc.
From 2007 to 2008, Mr. Xue was the Deputy Director of the
Chinese Red Cross Rescue Training Department, Vice President of the
Business Development Department of Haihong Pharmaceutical Holdings;
in 2009 Mr. Xue founded Mai Dingsheng International Medical
Investment Service Agency. From 2014 to the present, Mr. Xue is the
Deputy Dean of the International College of Natural Therapy,
Executive Vice President of the Zhongguancun Industry Integration
and Transformation Promotion Association and Chairman of the
International Medical Care Industry Committee, Deputy Director of
the Chronic Disease Prevention Fund Management Committee of the
China Medical and Health Development Foundation, Chinese
Nationality Deputy Director of the Internet + Medical Work
Committee of the Health Association, Deputy Director of the
Clinical Medicine Center of the Research Institute of the National
Health Commission. No transactions occurred since the beginning of
the Company's last fiscal year to which the Company was a party in
which Mr. Xue had or is to have a direct or indirect material
interest.
Mr. Rex Chang is an experienced GPA Consultant and an international
trade specialist. He started in manufacturing facilities,
well-trained in commercial and industrial, import-export, QC/QA,
marketing development and government procurement agreement fields.
Mr. Chang served as Chief Executive Officer in U. S. Asia Chamber
of Commerce, and Chief Executive Officer- Asian Marketing in U.S.
Foods International, he also served as Chief Executive Officer in
New Cathay International Development Corp. Mr. Chang also holds the
positions in Center for International Trade Development and Taiwan
Trade Center as Consultant. No transactions occurred since the
beginning of the Company's last fiscal year to which the Company
was a party in which Mr. Chang had or is to have a direct or
indirect material interest.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
AMERICA GREAT HEALTH
|
|
|
|
|
|
|
|
|
Dated: November 10, 2020
|
|
By:
|
/s/ Mike Q. Wang
|
|
|
|
President
|
|
|
|
|